Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04467021 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cancer and Blood Pressure Management, CARISMA Study

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Aug 31, 2026 → Aug 31, 2027
See other at-risk trials from ECOG-ACRIN Cancer Research Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2027 Show 5 more changesShow less
    • Secondary endpoints revised (8)
    • Study description revised
    • Site details revised at 4 of 25 sites
    • Publications: details revised at 2 of 2 entries
    • Eligibility criteria expanded, about 1 word
  2. 8 versions Re-verified since Nov 11, 2025, no change to tracked fieldsv13-v20
  3. Primary and study completion dates: Oct 31, 2025 to Aug 31, 2026v12
  4. Primary and study completion dates: Sep 1, 2025 to Oct 31, 2025v11
  5. Primary and study completion dates: Dec 31, 2024 to Sep 1, 2025v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary and study completion dates: Jun 29, 2024 to Dec 31, 2024v9
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 61
    • Site details revised at 25 of 25 sites
    v8
  3. Start date: Sep 1, 2020 to Oct 29, 2020v7
  4. Primary completion date: Oct 9, 2023 to Jun 29, 2024
    • Study completion date: Apr 9, 2024 to Jun 29, 2024
    v6
  5. Re-verified, no change to tracked fieldsv5
  6. Primary completion date: Feb 1, 2023 to Oct 9, 2023
    • Study completion date: Feb 1, 2023 to Apr 9, 2024
    v4
  7. Phase: Phase 2 to Not applicable
    • Study sites: 1 to 25
    v3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ECOG-ACRIN Cancer Research Group
59 trials monitored
See 7 trials at risk
Head & Neck Cancer
2,605 trials monitored
See 150 trials at risk
Chronic Kidney Disease
1,417 trials monitored
See 68 trials at risk
Kidney Cancer
889 trials monitored
See 68 trials at risk
and 1 more disease
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.
Trial Details
NCT Number NCT04467021
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8 +1 more
Related terms Carcinoma, Medullary, Carcinoma, Renal Cell, Cardiovascular Diseases, Renal Insufficiency, Chronic
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov